I am a pulmonary & critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.
Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, healthcare disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. My work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of my research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.
The main thrust of my work is currently on utilizing genetic data from diverse races to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Apr 04.
PMID: 38573068
A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis.
A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis. J Heart Lung Transplant. 2024 Mar 29.
PMID: 38556070
The Role of Inflammation and Fibrosis in ILD Treatment Decisions.
The Role of Inflammation and Fibrosis in ILD Treatment Decisions. Am J Respir Crit Care Med. 2024 Mar 14.
PMID: 38484133
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease. Am J Respir Crit Care Med. 2024 Feb 29.
PMID: 38422478
Home Oxygen After Hospitalization for COVID-19: Results From the Multi-Center OXFORD Study.
Home Oxygen After Hospitalization for COVID-19: Results From the Multi-Center OXFORD Study. Respir Care. 2024 Feb 28; 69(3):281-289.
PMID: 38176902
Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis.
Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis. Ann Am Thorac Soc. 2024 Feb 22.
PMID: 38386005
Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis.
Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis. ERJ Open Res. 2024 Jan; 10(1).
PMID: 38375425
Response.
Response. Chest. 2024 Feb; 165(2):e62-e63.
PMID: 38336452
Implementation of an Interstitial Lung Abnormality Clinic and Multidisciplinary Discussion.
Implementation of an Interstitial Lung Abnormality Clinic and Multidisciplinary Discussion. Respir Care. 2024 Jan 30.
PMID: 38290750
Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.
Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2024 Jan; 63(1).
PMID: 38237997